Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers
are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical …

Abnormal α-synuclein aggregation is a key pathological feature of a group of
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

Background Emerging evidence indicates that inflammasome-induced inflammation plays a
crucial role in the pathogenesis of Parkinson's disease (PD). Several proteins including α …

Parkinson's disease (PD) is the second most common progressive neurodegenerative
disorder mainly in middle‐elderly population, which represents diverse nonmotor symptoms …

Parkinson's disease (PD) is the second most common neurodegenerative disorder of the
elderly, presenting primarily with symptoms of motor impairment. The disease is diagnosed …

Parkinson's disease is the second most common neurodegenerative disorder after
Alzheimer's disease and is estimated to affect approximately 1–4% of individuals aged over …

Parkinson's disease (PD) is a complex neurodegenerative disorder with no cure in sight.
Clinical challenges of the disease include the inability to make a definitive diagnosis at the …